Breaking News

Avectas Expands Collaboration with CCRM and OmniaBio Inc.

Will enable the development of gene-edited induced pluripotent stem cells using Avectas' non-viral cell engineering platform, SOLUPORE.

Author Image

By: Charlie Sternberg

Associate Editor

Avectas, a cell engineering technology business and CCRM, with its subsidiary OmniaBio Inc., a CDMO that enables the development of cell therapies and associated technologies for clinical and commercial manufacture, have expanded their collaboration, to enable the development of gene-edited induced pluripotent stem cells (iPSCs) using Avectas’ non-viral cell engineering platform, SOLUPORE.   Cell therapies are transforming the treatment of diseases, including cancer, inflammation, and me...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters